Customer Center
Login | Register


Our xTAG® and MultiCode®-RTx Technologies serve a wide range of clinical applications, providing exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed.

Read More


Research & Applied Markets

Our xMAP® Technology and its flexible, open-architecture design is used in a wide variety of applications, from academic and clinical research to biodefense and clinical diagnostics.

Read More


Become a Partner

Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.

Learn More


Luminex® Blog

The Year Ahead: What to Expect in 2017

New funding, FDA clearances, and more

As we consider what 2017 has in store for the biomedical community, we’re pleased to kick off the year with the recent FDA clearance of our ARIES® GBS Assay for Streptococcus agalactiae (more commonly known as Group B Streptococcus). By most estimates, between 12 percent and 27 percent of pregnant women harbor GBS and can pass it on to their children during delivery. Here in the U.S., this pathogen is the leading cause of meningitis and sepsis in the first week of a newborn’s life…”

Continue Reading…

We Are Luminex

We Are Luminex


At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.

Watch more videos >

Luminex on Twitter

New research may help advance phage therapy. Learn more: by @ASMicrobiology #AMR
h J R
A new method for assessing the risk of #infectiousdisease outbreak by @SciReports
h J R
Experts explore @CDCgov "Winnable Battles” in infectious disease by @Contagion_Live
h J R

Latest News

January 9
Luminex Announces Preliminary Revenue for Fourth Quarter 2016 and Issues 2017 Revenue Guidance; To Present at 35th Annual J.P. Morgan Healthcare Conference

January 4
Luminex Corporation Receives FDA Clearance for ARIES® GBS Assay

December 5
Luminex wins R&D 100 Award for ARIES Systems

November 17
ARIES System and Flu A/B & RSV Assay Evaluated by Erasmus MC in New Publication

November 7
Luminex Corporation To Present At The 28th Annual Piper Jaffray Healthcare Conference

October 31
Luminex Corporation Reports Third Quarter 2016 Results; Raises Full Year Guidance


First Coast Infectious Disease/Clinical Microbiology Symposium
January 27-28
St. Augustine, FL

ASM Biothreats: Research, Response & Policy Meeting
February 6-8
Washington, DC

NCASM Spring Meeting
March 3-4
San Francisco, CA

FAH Public Policy Conference & Business Expo
March 5-7
Washington, DC

SCACM Spring Meeting
March 23-25
Indianapolis, IN